AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25189856 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (0.45 g/kg)
Number of subjects: 87
Study 25189856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 23432189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 7447
Study 23432189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 7447
Study 23432189 — intervention group
Group type: COMPARATOR
Intervention: Control diet (advice to reduce dietary fat)
Number of subjects: 7447
Study 21135532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowatinex® (special terpene combination; 3 × 2 capsules/day)
Number of subjects: 222
Study 21135532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 19076984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0
Study 19076984 — intervention group
Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 0
Study 17229225 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole magnesium 20.6 mg o.m. (Ome-Mg 20)
Number of subjects: 31
Study 17229225 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 10 mg b.d. (Fam 10)
Number of subjects: 31
Study 17229225 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg b.d. (Fam 20)
Number of subjects: 31
Study 15029940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace with minimal tension
Number of subjects: 15
Study 15029940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace with 25‐N tension
Number of subjects: 15
Study 15029940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace with 50‐N tension
Number of subjects: 15
Study 15029940 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 15
Study 11677969 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal epinephrine injection (1:10,000) before polypectomy
Number of subjects: 120
Study 11677969 — intervention group
Group type: COMPARATOR
Intervention: No injection (control group) before polypectomy
Number of subjects: 120
Study 9476184 — intervention group
Group type: COMPARATOR
Intervention: Intravenous L-arginine
Number of subjects: 8
Study 9476184 — intervention group
Group type: COMPARATOR
Intervention: Chronic oral intake of L-arginine
Number of subjects: 8
Study 7946898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 micrograms/d for 8 weeks
Number of subjects: 0
Study 7946898 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro supplementation with 1 x 10(‐7) M Se (as sodium selenite)
Number of subjects: 0
Study 2892807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (5 mg)
Number of subjects: 6
Study 2892807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (10 mg)
Number of subjects: 6
Study 2892807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (20 mg)
Number of subjects: 6
Study 2892807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31163053 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of past week alcohol consumption prior to the AUDIT-C screening
Number of subjects: 2379
Study 31163053 — intervention group
Group type: COMPARATOR
Intervention: AUDIT-C screening after past week alcohol consumption assessment
Number of subjects: 2379
Study 28461224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 5887
Study 28461224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5887
Study 25017108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasal prongs
Number of subjects: 78
Study 25017108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasal mask
Number of subjects: 78
Study 25017108 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating mask/prongs
Number of subjects: 78
Study 23559149 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus standard weekly cetuximab (arm 1)
Number of subjects: 152
Study 23559149 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab (500 mg/m(2)) every second week (arm 2)
Number of subjects: 152
Study 21752025 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided messages
Number of subjects: 336
Study 21752025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-NFC individuals
Number of subjects: 336
Study 21752025 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate time pressure
Number of subjects: 336
Study 21752025 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided messages under low or moderate time pressure for high-NFC individuals
Number of subjects: 336
Study 21752025 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sided messages under low or high time pressure for low-NFC individuals
Number of subjects: 336
Study 21752025 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided messages under moderate time pressure for low-NFC individuals
Number of subjects: 336
Study 19259629 — intervention group
Group type: EXPERIMENTAL
Intervention: 303 Algorithm
Number of subjects: 193
Study 19259629 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 193
Study 16765862 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway for treating pneumonia in nursing homes; Details: Not specified
Number of subjects: 7
Study 14675411 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75-250 mg/d)
Number of subjects: 55
Study 14675411 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 55
Study 14579019 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous epidural neurolysis according to Racz's technique
Number of subjects: 25
Study 10467476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% (n = 10)
Number of subjects: 29
Study 10467476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (n = 10)
Number of subjects: 29
Study 10467476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (n = 9)
Number of subjects: 29
Study 8849189 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune and scarification Bacillus Calmette-Guerin (BCG)
Number of subjects: 43
Study 8849189 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 43
Study 2142225 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Number of subjects: 25
Study 649865 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana with no motivation instructions
Number of subjects: 112
Study 649865 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana with 'try as hard as possible' instructions
Number of subjects: 112
Study 649865 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana with small monetary incentive
Number of subjects: 112
Study 649865 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana with substantial monetary incentive
Number of subjects: 112
Study 649865 — intervention group
Group type: COMPARATOR
Intervention: No drug with no motivation instructions
Number of subjects: 112
Study 649865 — intervention group
Group type: COMPARATOR
Intervention: No drug with 'try as hard as possible' instructions
Number of subjects: 112
Study 649865 — intervention group
Group type: COMPARATOR
Intervention: No drug with small monetary incentive
Number of subjects: 112
Study 649865 — intervention group
Group type: COMPARATOR
Intervention: No drug with substantial monetary incentive
Number of subjects: 112
Study 31616939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cousers of cannabis and tobacco
Number of subjects: 1078
Study 30958544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5µg twice daily for 2 weeks, then 10µg twice daily for 4 weeks
Number of subjects: 10
Study 30958544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 10
Study 28603135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel combined with pantoprazole treatment
Number of subjects: 478
Study 28603135 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel treatment alone (Control)
Number of subjects: 478
Study 27107896 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time kinematic biofeedback
Number of subjects: 30
Study 25141114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Manguinhos epoetin
Number of subjects: 74
Study 25141114 — intervention group
Group type: COMPARATOR
Intervention: Biosimilar epoetin
Number of subjects: 74
Study 23095282 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor-α therapy
Number of subjects: 17
Study 23095282 — intervention group
Group type: COMPARATOR
Intervention: Stable cardiovascular disease (control group)
Number of subjects: 17
Study 19631849 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for periodontal diseases
Number of subjects: 0
Study 19631849 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated treatment of periodontic and endodontic diseases
Number of subjects: 0
Study 17442840 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NT)
Number of subjects: 74
Study 17442840 — intervention group
Group type: COMPARATOR
Intervention: Strength training (ST)
Number of subjects: 74
Study 15572280 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (active injections, dummy oral)
Number of subjects: 640
Study 15572280 — intervention group
Group type: COMPARATOR
Intervention: Oral risperidone (dummy injections, active oral)
Number of subjects: 640
Study 11988132 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate with 0.625 mg conjugated equine estrogens (CEE)
Number of subjects: 24
Study 11988132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic etidronate with 0.625 mg CEE
Number of subjects: 24
Study 11988132 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate with 2 mg estradiol (E2)
Number of subjects: 24
Study 11988132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone with fluoride
Number of subjects: 24
Study 11988132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent etidronate with fluoride
Number of subjects: 24
Study 11988132 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens (nandrolone decanoate plus calcitonin, calcitonin plus growth hormone (GH), pamidronate plus GH)
Number of subjects: 24
Study 9808143 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol) intravenously at doses ranging from 0.04 to 0.24 microg/kg
Number of subjects: 35
Study 9808143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9808143 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol) at 0.16 and 0.24 microg/kg
Number of subjects: 35
Study 9808143 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol)
Number of subjects: 35
Study 9808143 — intervention group
Group type: COMPARATOR
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol) and Placebo
Number of subjects: 35
Study 7702151 — intervention group
Group type: EXPERIMENTAL
Intervention: neuroleptanaesthesia
Number of subjects: 20
Study 7702151 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane‐based anaesthesia
Number of subjects: 20
Study 7702151 — intervention group
Group type: COMPARATOR
Intervention: both anaesthesia techniques
Number of subjects: 20
Study 29335386 — intervention group
Group type: EXPERIMENTAL
Intervention: CorPath GRX system
Number of subjects: 40
Study 27589047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033
Study 27589047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study 24748179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided procedure
Number of subjects: 214
Study 24748179 — intervention group
Group type: COMPARATOR
Intervention: Seldinger's technique
Number of subjects: 214
Study 28075228 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening
Number of subjects: 141578
Study 28075228 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 141578
Study 20568377 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of oral prednisone daily for 2 weeks
Number of subjects: 59
Study 20568377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 18436033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 43
Study 18436033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg/0.5 mg naloxone
Number of subjects: 43
Study 18436033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18436033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg/0.5 mg naloxone (females)
Number of subjects: 43
Study 16965204 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Behavioral Intervention (EBI), N = 35
Number of subjects: 61
Study 16965204 — intervention group
Group type: COMPARATOR
Intervention: Routine Care Intervention (RCI), N = 27
Number of subjects: 61
Study 14576659 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (7.5 mg intravenously weekly for 12 weeks)
Number of subjects: 100
Study 14576659 — intervention group
Group type: COMPARATOR
Intervention: Control (standard immunization schedule)
Number of subjects: 100
Study 10737581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously at induction of anesthesia
Number of subjects: 84
Study 10737581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 9014625 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1 followed by a 9‐mg kg‐1 h‐1 continuous infusion
Number of subjects: 37
Study 9014625 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg kg‐1 followed by a 15‐mg kg‐1 h‐1 continuous infusion
Number of subjects: 37
Study 9014625 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone group
Number of subjects: 37
Study 9014625 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol group
Number of subjects: 37
Study 1515878 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (TBI dose 9 Gy)
Number of subjects: 144
Study 1515878 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (increased TBI dose rate and anthracyclines)
Number of subjects: 144
Study 1515878 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (TBI dose 12 Gy, no anthracyclines)
Number of subjects: 144
Study 3924719 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms/day
Number of subjects: 0
Study 3924719 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1.2 g/day
Number of subjects: 0
Study 31407775 — intervention group
Group type: COMPARATOR
Intervention: Nasal cast with elastic bandage (group 2)
Number of subjects: 60
Study 31407775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration treatment in addition to nasal cast with elastic bandage (group 3)
Number of subjects: 60
Study 29997457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans MTCC 5856
Number of subjects: 40
Study 29997457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28606184 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI)
Number of subjects: 2550
Study 28606184 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2550
Study 26562491 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies in the PLEASANT trial
Number of subjects: 142
Study 23767097 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin (150 mg, two-week infusion)
Number of subjects: 0
Study 23767097 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin (400 ml, two-week infusion)
Number of subjects: 0
Study 23767097 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg, two-week infusion)
Number of subjects: 0
Study 23767097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20352318 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm with lubricant gel
Number of subjects: 4925
Study 20352318 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4925
Study 20352318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal practices (washing, wiping, insertion of dry or absorbent materials)
Number of subjects: 4925
Study 20352318 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing, wiping, and insertion practices
Number of subjects: 4925
Study 18822903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Jianpi Recipe (BSJPR)
Number of subjects: 117
Study 18822903 — intervention group
Group type: COMPARATOR
Intervention: Liver protecting remedy (silymarin and vitamin C)
Number of subjects: 117
Study 16874758 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS)
Number of subjects: 42
Study 12514673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 60 mg daily for 11 months
Number of subjects: 47
Study 12514673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared mental models organization
Number of subjects: 0
Study 11104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of overlap between team members' mental models
Number of subjects: 0
Study 9015908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (10, 20, 40 mg)
Number of subjects: 230
Study 9015908 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50, 100 mg)
Number of subjects: 230
Study 1726000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily
Number of subjects: 0
Study 1726000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg once daily
Number of subjects: 0
Study 6738365 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day ursodeoxycholic acid
Number of subjects: 16
Study 6738365 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg/day lactose
Number of subjects: 16
Study 30545532 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) infusion (0.5-1 cc) in addition to HRT
Number of subjects: 83
Study 30545532 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT) only
Number of subjects: 83
Study 27481035 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 60
Study 27481035 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 60
Study 27481035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inspiratory muscle training and functional electrical stimulation
Number of subjects: 60
Study 27481035 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 24139708 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP‐I programme
Number of subjects: 308
Study 24139708 — intervention group
Group type: COMPARATOR
Intervention: Control wards (standard health-care practice)
Number of subjects: 308
Study 23566914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated 20% 5-aminolevulinic acid (ALA) photodynamic therapy (PDT)
Number of subjects: 151
Study 23566914 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 151
Study 23566914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated 20% 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) for tumors >0.7 mm
Number of subjects: 151
Study 23566914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated 20% 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) for tumors ≤0.7 mm
Number of subjects: 151
Study 20526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 50 mg + Ondansetron 4 mg
Number of subjects: 702
Study 20526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 100 mg + Ondansetron 4 mg
Number of subjects: 702
Study 20526194 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 150 mg + Ondansetron 4 mg
Number of subjects: 702
Study 20526194 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg alone
Number of subjects: 702
Study 19055987 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose (LD) / 75 mg maintenance dose (MD) for 28 days
Number of subjects: 110
Study 19055987 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD) for 28 days
Number of subjects: 110
Study 17285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Number of subjects: 0
Study 17285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approaches
Number of subjects: 0
Study 17285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant radiotherapy
Number of subjects: 0
Study 17285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy with intersphincteric dissection
Number of subjects: 0
Study 17285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Local resection through a trans-anal approach
Number of subjects: 0
Study 17285082 — intervention group
Group type: EXPERIMENTAL
Intervention: Future strategies
Number of subjects: 0
Study 15239618 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior (CEL) solution
Number of subjects: 441
Study 15239618 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 441
Study 11300450 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 50
Study 11300450 — intervention group
Group type: COMPARATOR
Intervention: Active pedal plantarflexion
Number of subjects: 50
Study 9278210 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO), 250 mg daily for 2 days
Number of subjects: 0
Study 8220156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 200 mg/m2/day by continuous infusion for seven days
Number of subjects: 102
Study 8220156 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine 500 mg/m2 every 12 hours for 12 doses (intermediate-dose)
Number of subjects: 102
Study 8220156 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 60
Number of subjects: 102
Study 8220156 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <= 60
Number of subjects: 102
Study 3308980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin alone
Number of subjects: 15